
Silver Research
Contact
233 South 10th Street
Office and Lab Suite 309
Philadelphia, PA 19107
Highlighted Publications
Neupane M, Clark AP, Landini S, Birkbak NJ, Eklund AC, Schumacher SE, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver DP. MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy. Cancer Discovery 2016 Jan; 6(1): 45-58.
We describe the first generation screen for new oncogenes and the initial characterization of a novel commonly amplified oncogene, MECP2.
Birkbak NJ, Wang ZC, Kim JY, Ecklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, *Silver DP, *Szallasi Z, *Richardson AL. Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discovery 2012; Apr; 2(4):366-75. (*co-senior authors)
This paper describes the first biomarker of chemotherapy response derived from counting the number of a specific kind of chromosomal abnormality.
Telli ML, Timms K, Reid J , Hennessy B, Mills G, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones J, Lanchbury JS, Hartman A, Garber JE, Ford JM, Silver DP*, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. Clinical Cancer 2016 Aug; 22(15), 3764–3773. *Corresponding author*
Here we demonstrate the utility of a biomarker of chemotherapy response based upon telomeric allelic imbalance.